EXELIXIS INC

NASDAQ: EXEL (Exelixis, Inc.)

Last update: 4 days ago, 8:50AM

35.31

0.85 (2.47%)

  • 1D 2.47%
  • 5D 2.14%
  • 1M -4.62%
  • 6M 20.31%
  • YTD 4.04%
  • 1Y 54.73%
  • 5Y 90.56%
Previous Close 34.46
Open 34.68
Volume 2,075,284
Avg. Volume (3M) 2,774,411
Market Cap 9,882,598,400
Price / Earnings (TTM) 20.06
Price / Earnings (Forward) 15.85
Price / Sales 4.76
Price / Book 4.35
52 Weeks Range
20.14 (-42%) — 40.02 (13%)
Earnings Date 28 Apr 2025 - 2 May 2025
Profit Margin 24.04%
Operating Margin (TTM) 28.84%
Diluted EPS (TTM) 1.76
Quarterly Revenue Growth (YOY) 18.20%
Quarterly Earnings Growth (YOY) 63.50%
Total Debt/Equity (MRQ) 9.62%
Current Ratio (MRQ) 3.63
Operating Cash Flow (TTM) 699.97 M
Levered Free Cash Flow (TTM) 464.22 M
Return on Assets (TTM) 14.64%
Return on Equity (TTM) 23.13%

Market Trend

Short Term Medium Term
Industry Biotechnology (US) Mixed Mixed
Biotechnology (Global) Mixed Mixed
Stock Exelixis, Inc. Bullish Bullish

AIStockmoo Score

-0.3
Analyst Consensus 1.5
Insider Activity 3.0
Price Volatility -0.5
Technical Moving Averages -5.0
Technical Oscillators -0.5
Average -0.30

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
EXEL 10 B - 20.06 4.35
CORT 7 B - 56.58 10.65
VKTX 3 B - - 2.88
PTGX 3 B - 9.67 3.87
APLS 2 B - - 10.24
ACAD 2 B - 10.72 3.21

Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
Sector Healthcare
Industry Biotechnology
Investment Style Small Growth
% Held by Insiders 1.84%
% Held by Institutions 92.05%
52 Weeks Range
20.14 (-42%) — 40.02 (13%)
Price Target Range
29.00 (-17%) — 45.00 (27%)
High 45.00 (Citigroup, 27.44%) Buy
Median 39.00 (10.45%)
Low 29.00 (Barclays, -17.87%) Hold
29.00 (Stephens & Co., -17.87%) Hold
Average 37.57 (6.40%)
Total 8 Buy, 6 Hold
Avg. Price @ Call 33.75
Firm Date Target Price Call Price @ Call
HC Wainwright & Co. 27 Mar 2025 40.00 (13.28%) Buy 36.84
13 Feb 2025 40.00 (13.28%) Buy 34.49
RBC Capital 13 Mar 2025 40.00 (13.28%) Buy 36.80
Wells Fargo 24 Feb 2025 36.00 (1.95%) Hold 37.13
Barclays 13 Feb 2025 29.00 (-17.87%) Hold 34.49
Citigroup 12 Feb 2025 45.00 (27.44%) Buy 32.80
Guggenheim 12 Feb 2025 42.00 (18.95%) Buy 32.80
Piper Sandler 12 Feb 2025 38.00 (7.62%) Buy 32.80
Stephens & Co. 12 Feb 2025 29.00 (-17.87%) Hold 32.80
27 Jan 2025 29.00 (-17.87%) Hold 32.73
Stifel 12 Feb 2025 36.00 (1.95%) Hold 32.80
UBS 28 Jan 2025 34.00 (-3.71%) Hold 32.60
JMP Securities 27 Jan 2025 41.00 (16.11%) Buy 32.73
23 Jan 2025 41.00 (16.11%) Buy 34.13
Morgan Stanley 27 Jan 2025 40.00 (13.28%) Buy 32.73
Truist Securities 27 Jan 2025 43.00 (21.78%) Buy 32.73
Oppenheimer 24 Jan 2025 33.00 (-6.54%) Hold 32.38
16 Jan 2025 41.00 (16.11%) Buy 36.55
Show more

No data within this time range.

  • 3M
Date Type Details
26 Mar 2025 Announcement Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors
25 Mar 2025 Announcement Exelixis to Present Positive Preclinical Data Across Its Pipeline Portfolio for Advanced Cancers at AACR 2025
08 Mar 2025 Announcement Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge
25 Feb 2025 Announcement Exelixis to Webcast Fireside Chats at Upcoming Investor Conferences in March
20 Feb 2025 Announcement Exelixis Announces a Newly Authorized $500 Million Stock Repurchase Program
15 Feb 2025 Announcement Exelixis Announces Final Five-Year Follow-up Results from CheckMate -9ER Trial Evaluating CABOMETYX® (cabozantinib) in Combination with Opdivo® (nivolumab) in Patients with Advanced Kidney Cancer at ASCO GU 2025
13 Feb 2025 Announcement Exelixis to Participate in the Citi 2025 Virtual Oncology Leadership Summit
11 Feb 2025 Announcement Exelixis Announces Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Corporate Update
28 Jan 2025 Announcement Exelixis to Release Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025
25 Jan 2025 Announcement Exelixis Announces Encouraging Results from Phase 1b/2 STELLAR-001 Trial Evaluating Zanzalintinib Alone or in Combination with an Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer at ASCO GI 2025
24 Jan 2025 Announcement Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Study Evaluating Cabozantinib in Advanced Gastrointestinal Neuroendocrine Tumors Presented at ASCO GI 2025
Show more

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2025 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria